Published in Front Immunol on August 10, 2015
Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway. J Immunol (2016) 0.80
Molecular alterations in the TCR signaling pathway in patients with aplastic anemia. J Hematol Oncol (2016) 0.75
CD28 days later: Resurrecting costimulation for CD8(+) memory T cells. Eur J Immunol (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 12.50
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 6.93
Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release. J Exp Med (1984) 5.54
T cell activation determined by T cell receptor number and tunable thresholds. Science (1996) 5.51
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science (1992) 5.36
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 4.53
Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest (2003) 4.14
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
T cell memory. Annu Rev Immunol (2001) 3.70
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Dendritic cells maximize the memory CD8 T cell response to infection. Immunity (2005) 3.21
No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol (2002) 3.20
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A (1992) 2.98
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol (1994) 2.86
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol (2009) 2.66
Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol (2007) 2.61
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
Allo-HLA reactivity of virus-specific memory T cells is common. Blood (2010) 2.28
T cell allorecognition via molecular mimicry. Immunity (2009) 2.25
Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant (2002) 2.18
Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol (2000) 2.17
CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev (2005) 2.16
Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity (1996) 2.08
An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med (1994) 2.02
Distinct features of dendritic cells and anti-Ig activated B cells as stimulators of the primary mixed leukocyte reaction. J Exp Med (1989) 2.00
Antibody-mediated organ-allograft rejection. Nat Rev Immunol (2005) 1.99
Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med (2011) 1.97
Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol (2001) 1.96
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96
Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev (2003) 1.76
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76
CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75
Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol (2006) 1.73
T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol (2002) 1.73
Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. Immunity (2009) 1.70
Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev (2009) 1.66
The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity (2014) 1.64
The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol (2013) 1.63
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Exp Med (1998) 1.62
Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol (2003) 1.61
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med (2008) 1.56
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol (1997) 1.55
Reactions of the graft versus host (GVH) type. Aust J Exp Biol Med Sci (1969) 1.49
Memory CD8+ T cells require CD28 costimulation. J Immunol (2007) 1.45
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res (2011) 1.42
Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med (1999) 1.42
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol (2011) 1.40
Allogeneic stimulation modulates the in vitro response of T cells to transplantation antigen. Nature (1974) 1.37
Activation of naive, memory and effector T cells. Curr Opin Immunol (1994) 1.34
Cell surface signaling molecules in the control of immune responses: a tide model. Immunity (2011) 1.32
Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol (2003) 1.31
Lineage relationship of effector and memory T cells. Curr Opin Immunol (2013) 1.30
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol (2004) 1.28
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol (1995) 1.25
Activation rules: the two-signal theories of immune activation. Nat Rev Immunol (2002) 1.22
Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol (2008) 1.22
Memory T cells need CD28 costimulation to remember. Semin Immunol (2009) 1.22
Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int (2011) 1.21
Role of ICOS versus CD28 in antiviral immunity. Eur J Immunol (2002) 1.20
Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant (2014) 1.19
Critical role of CD28 in protective immunity against Salmonella typhimurium. J Immunol (1999) 1.18
Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol (2009) 1.18
Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med (2010) 1.17
Role of CD28 for the generation and expansion of antigen-specific CD8(+) T lymphocytes during infection with Listeria monocytogenes. J Immunol (2001) 1.16
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest (2004) 1.14
CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol (2006) 1.11
Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant (2008) 1.11
Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol (2012) 1.08
CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol (2000) 1.07
High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am J Transplant (2014) 1.05
Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant (2011) 1.02
Allorecognition pathways in transplant rejection and tolerance. Transplantation (2013) 1.02
Bone marrow-derived cells expand memory CD8+ T cells in response to viral infections of the lung and skin. Eur J Immunol (2006) 1.01
Role of CD28 in the generation of effector and memory responses required for resistance to Toxoplasma gondii. J Immunol (1999) 1.01
Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation (2001) 0.97
Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol (2011) 0.97
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant (2012) 0.96
Expansion of effector memory TCR Vbeta4+ CD8+ T cells is associated with latent infection-mediated resistance to transplantation tolerance. J Immunol (2008) 0.95